52 Week Range
As of on the NASDAQ ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Biontech And Pfizer Announce Completion Of Dosing For First Cohort Of Phase 1/2 Trial Of Covid-19 Vaccine Candidates In Germany
Biontech, Pfizer Announce Regulatory Approval From German Authority To Commence First Clinical Trial Of Covid-19 Vaccine Candidates
Pfizer and BioNTech to Co-Develop Potential COVID-19 Vaccine
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. It develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Biotechnology & Drugs
An der Goldgrube 12
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
GSK <GSK.L>, the world's largest vaccine maker, laid out plans on Thursday to produce 1 billion doses of vaccine efficacy boosters for COVID-19 shots next year, as the race to develop a successful solution to the coronavirus crisis heats up.
Drugmakers are rushing to develop a treatment or vaccine for the fast-spreading new coronavirus that has killed over 345,433 people and ravaged financial markets. Gilead Sciences Inc's antiviral remdesivir could be at the forefront of the fight against the virus, after getting...
Thailand expects to have a vaccine for the novel coronavirus ready next year, a senior official said on Wednesday, after finding positive trial results in mice.
AstraZeneca Plc said it was in talks with governments around the world to strike coronovirus vaccine production deals similar to one it agreed with Britain over the weekend.
A keenly-watched COVID-19 vaccine will be priced to allow as wide as possible access to it, if it proves successful, and will be made at huge scale to keep costs down and supply up, said the Oxford University professor co-leading its development.
A closely watched coronavirus vaccine being developed by scientists at Oxford University appears protective in a small study of six monkeys, promising findings that led to the start of human trials late last month, U.S. and British researchers reported on Thursday.
Germany's unlisted CureVac said its experimental coronavirus vaccine was shown to trigger an immune response in animals when given a low dose and the biotech firm was looking at carrying out its first human trials in June.
Moderna Inc said on Tuesday the U.S. Food and Drug Administration granted "fast track" designation to its experimental coronavirus vaccine, a move that speeds up the regulatory review process.
Pfizer Inc <PFE.N> and BioNTech SE <22UAy.F> said on Tuesday they have begun delivering doses of their experimental coronavirus vaccines for initial human testing in the United States.
Moderna Inc said on Thursday it expects mid-stage trials for its COVID-19 vaccine to begin shortly while late-stage trials are expected to begin early summer, as the drug developer accelerates its efforts to combat the pandemic.
Moderna Inc sped up plans for its experimental COVID-19 vaccine on Thursday and said it expected to start a late-stage trial in early summer, pushing ahead in the race for developing a safe and effective vaccine.
Der französische Arzneimittelhersteller Sanofi will mit dem Start einer klinischen Studie die Wirksamkeit von zwei experimentellen Impfstoffen gegen das neuartige Coronavirus SARS-CoV-2 überprüfen. Während Phase-I-Impfstoffstudien in der Regel eine kleine Anzahl gesunder...
French drugmaker Sanofi SA <SASY.PA> said it plans to enroll thousands of subjects globally for trials of an experimental vaccine for the coronavirus it is developing with GlaxoSmithKline Plc <GSK.L>, and that it has started to discuss advanced purchases with several countries...
Pfizer aims to make 10-20 million doses of a coronavirus vaccine it is developing with Germany's BioNtech by the end of 2020 for emergency use should it pass tests, the U.S. drugmaker's head of vaccines said on Thursday.
Pfizer <PFE.N> aims to make 10-20 million doses of a coronavirus vaccine it is developing with Germany's BioNtech <22UAy.F> by the end of 2020 for emergency use should it pass tests, the U.S. drugmaker's head of vaccines said on Thursday.
* ANNOUNCE COMPLETION OF DOSING FOR FIRST COHORT OF PHASE 1/2 TRIAL OF COVID-19 VACCINE CANDIDATES IN GERMANY
Pfizer Inc <PFE.N> on Tuesday said it expects its experimental coronavirus vaccine to move into expanded clinical trials by October that could allow for emergency use or accelerated approval, as it ramps up efforts to combat the pandemic.
By Julie Steenhuysen, Peter Eisler, Allison Martell and Stephanie Nebehay
The following are some of the factors that may move German stocks on Monday:
German biotech company BioNTech <22UAy.F>, which has approval for human trials of potential coronavirus vaccines, has lately been contacted by industry players but is not interested in a takeover, a newspaper reported on Saturday.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.